Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasoph... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Clinical and Economic Outcomes of Adding Semaglutide to Standard of Care in Adult ... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with In... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety o... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, placebo-controlled multiple dose study to characterize the effects of LY408... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Platelet-Rich Plasma with Hyaluronic Acid Injections for Post- Viral Olfactory loss. A double-bli... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Leveraging AS01-induced immune cell reprogramming to modulate immune dysregulation in rheumatoid ... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES... Read More